FTSE 100 news / Companies and sectors / Pharma and healthcare / 14 October 2026
Pharma and healthcare: sector news on Wednesday 14 October 2026
Average tone +3.2 (positive) across 5 companies with relevant coverage, from 38 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +2.3 | 20 | Coverage centred on the Pennsylvania manufacturing expansion and routine insider dividend reinvestments, plus previews of the third-quarter results. |
| AstraZeneca | +5.0 | 10 | Coverage was mostly positive, with a new $1 billion R&D hub, a Saudi approval for Baxfendy, a $2 billion deal and supportive analyst ratings. |
| Convatec | +0.3 | 4 | Coverage was mixed: a former employee is seeking £366M in a patent profit-share claim and a costly InnovaMatrix write-down was discussed. |
| Haleon | +4.5 | 2 | Coverage of Haleon was mainly valuation commentary and a push behind its Excedrin brand. |
| Smith & Nephew | +4.0 | 2 | Coverage centred on a US product launch for pressure ulcer devices and a discussion of whether the company's American knee business can recover once Landmark reaches surgeons. |
Strongest stories in the sector
- +10.0 AstraZeneca Opens $1 Billion R&D Hub, Plans 50% Workforce Growth
New $1 billion R&D hub and planned workforce growth. - +9.2 Saudi FDA approves BAXFENDY (baxdrostat) for adults with uncontrolled and resistant hypertension
Saudi approval of Baxfendy for hypertension. - +9.2 GSK Announces Drug Manufacturing Expansion In Pennsylvania
Manufacturing expansion in Pennsylvania signals investment and growth. - +8.7 Why ConvaTec's (LSE:CTEC) buyback and raised interim payout keep the FTSE 100 medtech on income radars
Buyback and raised interim dividend are shareholder-friendly and positive. - −8.3 AstraZeneca details Phase III HICKORY endpoint miss for efzimfotase alfa in hypophosphatasia
Phase III HICKORY trial missed endpoint. - +8.3 GSK Sets 2027 Construction Start for $800M Pennsylvania Buildout - Engineering News-Record
$800M Pennsylvania buildout confirms major investment plans. - −7.5 Ex-Convatec Worker Seeks £366M From Patent Profit Share
Former worker seeking £366M patent profit share is a legal risk for Convatec. - +7.0 Barclays Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $211.48
Barclays maintains Buy rating and target. - +6.7 AstraZeneca completed USD 2 billion deal: analysts target AstraZeneca stock at USD 206.67 - ad-hoc-news.de
Completed $2 billion deal with analyst targets above price. - +6.3 Stockholm stock market opens higher with AstraZeneca leading the way, OMXS30 index up 0.5 percent
AstraZeneca led Stockholm market higher. - +5.7 Haleon (LSE:HLN) Unveils Excedrin Push, Is The Valuation Gap An Opportunity?
Excedrin product push and valuation gap framed as opportunity. - +5.3 Pressure Ulcer Devices Market: Smith+Nephew Launches U.S.
Smith+Nephew launching a pressure ulcer device in the US; product news.
Pharma and healthcare: every day · FTSE 100 overview for the day